menu
    • menu

    Company profile for Camurus

    NEW Drugs in Dev: 5
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Camurus is committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic conditions, including opioid dependence, pain, cancer and endocrine disorders. New investigational drug products are based on our proprietary FluidCrystal® drug delivery technologies with the purpose to deliver improved quality of life, treatment outcomes and resource utilization. The company’s...
    Camurus is committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic conditions, including opioid dependence, pain, cancer and endocrine disorders. New investigational drug products are based on our proprietary FluidCrystal® drug delivery technologies with the purpose to deliver improved quality of life, treatment outcomes and resource utilization. The company’s share is listed on Nasdaq Stockholm under the ticker “CAMX”.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    CamurusSweden Flag
    Country
    Country
    Sweden
    Address
    Address
    Ideon Science Park. SE-223 70 Lund
    Telephone
    Telephone
    +46 46 286 57 30
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.camurus.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Accepts Camurus' Oclaiz NDA Resubmission for Acromegaly
    FDA Accepts Camurus' Oclaiz NDA Resubmission for Acromegaly

    09 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/camurus-announces-fda-acceptance-of-nda-resubmission-for-oclaiz-for-the-treatment-of-acromegaly-302657390.html

    PR NEWSWIRE
    09 Jan 2026
    Share Share
    Camurus Reveals Positive Topline Data For CAM2056, Semaglutide
    Camurus Reveals Positive Topline Data For CAM2056, Semaglutide

    10 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/camurus-reports-positive-topline-results-for-cam2056-semaglutide-monthly-depot-302609929.html

    PR NEWSWIRE
    10 Nov 2025
    Share Share
    Camurus Launches Oczyesa Approval for Acromegaly in UK
    Camurus Launches Oczyesa Approval for Acromegaly in UK

    28 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/camurus-announces-approval-of-oczyesa-for-the-treatment-of-acromegaly-in-the-uk-302541276.html

    PR NEWSWIRE
    28 Aug 2025
    Share Share
    Camurus' Oczyesa® Gets EU Marketing Authorization for Acromegaly
    Camurus' Oczyesa® Gets EU Marketing Authorization for Acromegaly

    01 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/camurus-oczyesa-receives-marketing-authorization-for-treatment-of-acromegaly-in-the-eu-302495549.html

    PR NEWSWIRE
    01 Jul 2025
    Share Share
    Camurus`s Oczyesa Receives Approval in Europe
    Camurus`s Oczyesa Receives Approval in Europe

    30 Jun 2025

    // EMA

    https://www.ema.europa.eu/en/documents/overview/oczyesa-epar-medicine-overview_en.pdf

    EMA
    30 Jun 2025
    Share Share
    Camurus' POSITANO study: CAM2029 effects in liver disease
    Camurus' POSITANO study: CAM2029 effects in liver disease

    18 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/camurus-positano-study-shows-treatment-effects-with-cam2029-in-polycystic-liver-disease-patients-302484906.html

    PR NEWSWIRE
    18 Jun 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search